Skip to content

Study · Randomized controlled trial · n = 18 · 2011

4 results

The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen.

Kapitza C, Zdravkovic M, Hindsberger C, Flint A

Advances in therapy20 Jul 2011Cited by 27 (Europe PMC)

PMID21792552 (opens in a new tab)DOI10.1007/s12325-011-0044-y (opens in a new tab)PepBankPUB-21792552
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialPharmacokinetics

    In adults with type 2 diabetes, steady-state liraglutide 1.8 mg and placebo were equivalent for acetaminophen AUC(0-inf).

    In plain wordsIn adults with type 2 diabetes, liraglutide did not change the total acetaminophen exposure compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeAcetaminophen AUC(0-inf) with liraglutide
    Study

    n = 18

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1.8 mgAs given in this study (human).

    Measurements

    AUC(0-inf) ratio
    1.04
    liraglutide vs placebo

    Source sentences

    Summary
    Equivalence was demonstrated between liraglutide 1.8 mg at steady state and placebo, with respect to acetaminophen AUC(0-∞) (estimated ratio 1.04; 90% CI: 0.97, 1.10)
    2 context sentences
    Summary · context
    This was a randomized, placebo-controlled, two-period crossover trial in which subjects with type 2 diabetes received placebo or liraglutide.
    Summary · context
    After steady state PK of liraglutide 1.8 mg/ placebo were established, a single dose of acetaminophen 1 g was administered at the time of liraglutide C(max) (maximum concentration).
  2. 02HumanRandomized controlled trialPharmacokinetics

    In adults with type 2 diabetes, steady-state liraglutide 1.8 mg and placebo were equivalent for acetaminophen AUC(0-480) min.

    In plain wordsIn adults with type 2 diabetes, liraglutide did not change acetaminophen exposure over 8 hours compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeAcetaminophen AUC(0-480 min) with liraglutide
    Study

    n = 18

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1.8 mgAs given in this study (human).

    Measurements

    AUC(0-480) min ratio
    0.95
    liraglutide vs placebo

    Source sentences

    Summary
    acetaminophen AUC(0-480) min (estimated ratio 0.95; 90% CI: 0.89, 1.01).
    2 context sentences
    Summary · context
    This was a randomized, placebo-controlled, two-period crossover trial in which subjects with type 2 diabetes received placebo or liraglutide.
    Summary · context
    After steady state PK of liraglutide 1.8 mg/ placebo were established, a single dose of acetaminophen 1 g was administered at the time of liraglutide C(max) (maximum concentration).
  3. 03HumanRandomized controlled trialPharmacokinetics

    In adults with type 2 diabetes, liraglutide lowered the maximum acetaminophen concentration compared with placebo.

    In plain wordsIn adults with type 2 diabetes, liraglutide lowered the peak acetaminophen level compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseAcetaminophen Cmax with liraglutide
    Study

    n = 18

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1.8 mgAs given in this study (human).

    Measurements

    Cmax ratio
    0.69
    liraglutide vs placebo

    Source sentences

    Summary
    During liraglutide, a lower C(max) was observed (estimated ratio 0.69; 90% CI: 0.56, 0.85)
    2 context sentences
    Summary · context
    This was a randomized, placebo-controlled, two-period crossover trial in which subjects with type 2 diabetes received placebo or liraglutide.
    Summary · context
    After steady state PK of liraglutide 1.8 mg/ placebo were established, a single dose of acetaminophen 1 g was administered at the time of liraglutide C(max) (maximum concentration).
  4. 04HumanRandomized controlled trialPharmacokinetics

    In adults with type 2 diabetes, the median acetaminophen tmax occurred 15 minutes later with liraglutide than with placebo.

    In plain wordsIn adults with type 2 diabetes, acetaminophen reached its peak level 15 minutes later with liraglutide than with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseAcetaminophen tmax with liraglutide
    Study

    n = 18

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1.8 mgAs given in this study (human).

    Measurements

    tmax delay
    15 minutes
    liraglutide vs placebo

    Source sentences

    Summary
    the median acetaminophen t(max) occurred 15 minutes later compared with placebo.
    2 context sentences
    Summary · context
    This was a randomized, placebo-controlled, two-period crossover trial in which subjects with type 2 diabetes received placebo or liraglutide.
    Summary · context
    After steady state PK of liraglutide 1.8 mg/ placebo were established, a single dose of acetaminophen 1 g was administered at the time of liraglutide C(max) (maximum concentration).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT01517555

Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 18Oct 2006 to May 2007

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 26 Jan 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.